Manufacturer updates

A notice was received from AbbVie, effective July 1, 2025, changes to their Contract Pharmacy Policy including NDC additions (Emrelis and Emblaveo) and State exemptions (Colorado, North Dakota, South Dakota).

A notice was received from AbbVie, with varying effective dates, changes to their Contract Pharmacy Policy including additional state exemptions for Hawaii, Maine, Oklahoma, Rhode Island, Tennessee, Vermont, and Minnesota.

A notice was received from Abbvie, with an effective date of April 9, 2025, announcing the exemption of the state of Nebraska to their Contract Pharmacy Policy. 

A notice was received from AbbVie, effective February 27, 2025, several additions to their Contract Pharmacy Policy including additional NDC additions and Maryland exemption (with restrictions).

Effective January 1, 2025, Grantee covered entities that wish to facilitate bill to/ship to orders must register with 340B ESP and submit limited claims data on the 340B contract pharmacy utilization. There has also been a change to the Abbvie NDCS impacted by this policy. For more information, please visit https://340besp.com

Effective August 28, 2024, AbbVie will exempt Missouri covered entities from its 340B contract pharmacy policy.

Contact: 
support@340besp.com

Effective August 1, 2024, AbbVie will no longer extend 340B-like voluntary pricing on its orphan-designated drugs to covered entities subject to the orphan drug exclusion. This change will not impact separate agreements with impacted covered entities.  

Contact: 
support@340besp.com

Effective July 1, 2024, AbbVie will exempt Minnesota hospital covered entities from its 340B contract pharmacy policy.

Contact: 
support@340besp.com

Effective May 1st, 2024, AbbVie will allow Arkansas hospital covered entities to order 340B products and/or place “Bill to/Ship to” replenishment orders at the 340B ceiling price for its contract pharmacies.

Contact: 
support@340besp.com

Effective May 1, 2024, AbbVie will include Venclexta products in its 340B contract pharmacy policy. Federal Grantees are not subject to limitations. 

Contact: 
support@340besp.com

A notice was received from Alkermes, with an effective date of December 1, 2025, an update to their contract pharmacy policy regarding collection of claims data, a change in the system used for implementing the Policy, and State exemptions.

A notice was received from Alkermes, with an effective date of October 6, 2025, updating their contract pharmacy policy to exempt the states of Louisiana and Mississippi 

A notice was received from Alkermes, with varying effective dates, an update to their contract pharmacy policy exempting the states of North Dakota and Colorado.

A notice was received from Alkermes, with varying effective dates, an update to their contract pharmacy policy exempting the states of Maine (eff. Date 9/24/25) and Rhode Island (eff. Date 10/1/25). 

A notice was received from Alkermes, with varying effective dates, announcing the exemption of the states of Nebraska and Utah to their Contract Pharmacy Policy. 

A notice was received from Alkermes that effective March 3, 2025, Kansas and West Virginia are no longer exempt from their Contract Pharmacy Policy. 

Effective August 1, 2024, Alkermes will exempt Minnesota covered entities from its 340B contract pharmacy policy, in addition to Missouri covered entities from its 340B contract pharmacy policy effective 08.28.2024.
Contact: 
support@340besp.com

Effective July 22, 2024, Alkermes will exempt Arkansas, Louisiana, West Virginia, Mississippi, Maryland and Kansas covered entities from its 340B contract pharmacy policy.

Contact: 
support@340besp.com

Effective July 22nd, 2024, Alkermes will only provide 340B priced products to a single Contract Pharmacy of the Covered Entity does not have an in-house or wholly owned pharmacy. Covered entities located in Arkansas and Louisiana may use any contract pharmacies located in the respective states. Covered entities located in West Virginia are not subject to these restrictions.

Contact: 
support@340besp.com

A notice was received from Amgen, with varying effective dates, that they are suspending implementation of its HRSA-approved 340B Rebate Model Pilot Program and Enbrel will continue to be a part of their Contract Pharmacy Policy, and claims data submission is now required. 

A notice was received from Amgen, with an effective date of June 2, 2025, the exemption of the state of Tennessee to their Contract Pharmacy Policy.

A notice was received from Amgen, with varying effective dates, announcing the exemption of the states of Utah, South Dakota, and North Dakota to their Contract Pharmacy Policy.

Effective August 28, 2024, Amgen will exempt Missouri hospital covered entities from its 340B contract pharmacy policy 

Contact: 
support@340besp.com

Effective July 1, 2024, contract pharmacy arrangements between 340B covered entities located in Mississippi and Maryland and contract pharmacies located in each respective state are exempt from Amgen’s 340B contract pharmacy policy.

Contact: 
support@340besp.com

Effective April 2nd, 2024, contract pharmacy arrangements between 340B covered entities located in Arkansas and contract pharmacies located in Arkansas are exempt from Amgen’s 340B contract pharmacy policy.

Contact: 
support@340besp.com

Effective March 19th, 2024, Federal Grantees are no longer exempt from Amgen’s 340B contract pharmacy policy. Amgen will only provide 340B priced product to a single Contract Pharmacy located within 40 miles of the parent site if the covered entity doesn’t have an in-house pharmacy. If the covered entity does have an in-house pharmacy, they may designate a single contract pharmacy within 40 miles of the parent site with the provision of claims data.

Contact: 
support@340besp.com

Effective 07.01.24, Astellas announced a change to their 340B Contract Pharmacy Policy for Maryland & Mississippi covered entities. 

Effective May 1st, 2024, Astellas will include Myrbetriq products in its 340B contract pharmacy policy and only provide 340B pricing for Xtandi® and Myrbetriq ® products to a single contract pharmacy if a hospital covered entity doesn’t have an in-house pharmacy. 

Federal Grantees and covered entities in the state of Alabama* and Louisiana* are not subject to limitations.

*For contract pharmacies within the respective states

Contact: 
support@340besp.com

A notice was received from AZ, for an effective date of April 1, 2025, an update to their Contract Pharmacy to exempt Arkansas from the single contract pharmacy requirement (with data submission). 

A notice was received from AZ, for an effective date of April 1, 2025, to include Lynparza, Tagrisso, and Truqap to their Contract Pharmacy Policy restrictions.

Effective October 1, 2024 AstraZeneca requires data submission (within 45 date of dispense) through 340B ESP as a mandatory process for covered entities without an in-house pharmacy to enable a designated contract pharmacy. AirSupra® was added to their list of impacted products.  

Contact: support@340BESP.com

Effective March 12th, 2024, contract pharmacy arrangements between 340B covered entities located in Arkansas and contract pharmacies located in Arkansas are exempt from Bausch Health’s 340B contract pharmacy policy.

Contact: 
support@340besp.com

Bausch Health posted a notice on their website, effective October 1, 2025, their intent to cease participation in two optional Federal drug pricing programs – the Medicaid Drug Rebate Program (“MDRP”) and the 340B Drug Pricing Program (“340B”).

Effective July 1st, 2024, Bausch & Lomb will only provide 340B pricing on its products to a single contract pharmacy located within 40 miles of the parent site if the entity does not have an in-house pharmacy. 

Contact: 
support@340Besp.com

Effective October 1, 2024, Bayer will change to their 340B contract pharmacy policy to add federal grantees to their policy and require data submission within 45 days of date of dispense utilizing 340B ESP for all covered entities. 

Contact: 
support@340besp.com

Effective June 24th, 2024, Bayer will include Nubeqa to its 340B Contract Pharmacy Policy.

Contact: 
support@340besp.com

Effective May 1st, 2024, Arkansas-based covered entities will be able to place Bill to/Ship to replenishment orders through contract pharmacies located within Arkansas.

Contact: 
support@340besp.com

A notice was received from Biogen, with varying effective dates, the exemption of the states Maine, Oregon, and Rhode Island to their Contract Pharmacy Policy.

A notice was received from Biogen, with varying effective dates, the exemption of the state of North Dakota and Colorado to their Contract Pharmacy Policy.

A notice was received from Biogen, effective July 1, 2025, a change to their 340B Contract Pharmacy Policy exempting South Dakota and Hawaii* (*Partial exemption with claims data submission).

A notice was received from Biogen, effective July 1, 2025, a change to their 340B Contract Pharmacy Policy exempting South Dakota and Hawaii* (*Partial exemption with claims data submission).

A notice was received from Biogen, with an effective date of May 7, 2025, announcing the exemption of the state of Utah to their Contract Pharmacy Policy.

A notice was received from Biogen, with an effective date of April 10, 2025, the exemption of the state of Nebraska to their Contract Pharmacy Policy

Effective January 20, 2025 Biogen has made changes to their 340B contract pharmacy policy regarding all 340B covered entities (including hospital covered entities, federal grantee covered entities, and all contract pharmacies including wholly owned pharmacies). Data submission is also required via 340B ESP.  Arkansas, Louisiana, Kansas, Maryland, Minnesota, Missouri, Mississippi, and West Virigina are excluded from this policy.  

Effective 03.12.24, Biogen made a change to their 340B contract pharmacy policy regarding Arkansas covered entities.  

A notice was received from BMS, with varying effective dates, a change to their 340B Contract Pharmacy Policy exempting Vermont (eff. 7/10/25), Tennessee (eff. 7/1/25) and North Dakota (eff. 8/1/25). 

A notice was received from BMS, effective July 1, 2025, a change to their 340B Contract Pharmacy Policy exempting South Dakota.

A notice was received from BMS, with an effective date of July 1, 2025, a change to their Contract Pharmacy Policy, including Augtyro.

A notice was received from BMS, effective immediately, a change to their 340B contract pharmacy policy to require claims-level data to be submitted within 45 days (previously 14 days) and new addition of serialization data point. 

October 22, 2024, Update:  On October 22, 2024, BMS notified HRSA of BMS’ intention to implement a rebate model to carry out their 340B pricing obligations with an effective date of Spring 2025  

November 26, 2024, Update:  BMS sued HRSA over its purported rejection of BMS’ plan to change the way it offers reduced prices on its medicines in the 340B program. 

Contact: 
BMS340B@bms.com

As announced by the BMS third party solution, they have capabilities to accept serialization as of 9/3/2024. Per BMS, they are deferring the requirement for covered entities to submit the product serialization number to allow for additional time for DSCSA compliance stabilization. FDA exemption for serialization requirements for manufacturers through May 27th, 2025.

Contact: 
BMS340B@bms.com

Effective October 1, 2024, BMS will allow for a fourth contract pharmacy for Krazati ®

Contact: 
BMS340B@bms.com

Effective July 1, 2024, BMS will allow Maryland and Mississippi covered entities to order 340B products and/or place “Bill to/Ship to” replenishment orders at the 340B ceiling price for all contract pharmacies located in the respective state.

Contact: 
BMS340B@bms.com

Effective July 1st, 2024, BMS will recognize up to three designated 340B contract pharmacy locations per 340B hospital that lacks an entity-owned pharmacy: one for IMiDs, a second for non-IMiDs, and a third for Camzyos. Claims-level data must be submitted.

Contact: 
support@340besp.com

Effective immediately, BMS will allow Arkansas covered entities to use any contract pharmacies located in Arkansas to dispense BMS 340B-eligible outpatient drugs.

Contact: 
BMS340B@bms.com

Effective March 28th, 2024, BMS will allow Arkansas covered entities to use any contract pharmacies properly licensed by the Arkansas State Board of Pharmacy to dispense all 340B-eligible covered outpatient drugs.

Contact: 
BMS340B@bms.com

A notice was received from Boehringer Ingelheim, effective May 30, 2025, a change to their 340B contract pharmacy policy for Tennessee covered entities. Effective May 30, 2025, BI will require the submission of claims data for 340B utilization filled by covered entities in-house pharmacies. All specified claims must be submitted on the 340B ESP platform within 45 days of the date of dispense. 

Effective December 2, 2024, a change to their 340B contract pharmacy policy for requiring submission of claims data.

Effective June 6th, 2024, Boehringer Ingelheim will provide 340B pricing to an unlimited number of contract pharmacies located in West Virginia for covered entities in the state of West Virginia.

Contact: 
support@340Besp.com

Effective May 27th, 2024, Boehringer Ingelheim will provide 340B pricing to an unlimited number of contract pharmacies located in Louisiana for covered entities in the state of Louisiana.

Contact: 
support@340Besp.com

Effective May 1st, 2024, Boehringer Ingelheim will provide 340B pricing to an unlimited number of contract pharmacies located in Arkansas for covered entities in the state of Arkansas

Contact: 
support@340Besp.com

Beginning February 1, 2026, the products set forth below will only be available for purchase by 340B Covered Entities and their contract pharmacy agents at the 340B Ceiling Price directly from Camber through Direct Customer Solutions, LLC (“DCS”), the exclusive, national service provider to Camber for sales of our products at the 340B Ceiling Price. DCS will accept orders and provide logistics, invoicing, and customer support. Separately, DCS is also able to sell and distribute the referenced products to non-340B customers at commercial prices.

Beginning October 1, 2025, the products set forth in the attached will only be available for purchase by 340B Covered Entities and their contract pharmacy agents at the 340B Ceiling Price directly from Camber through Direct Customer Solutions, LLC (“DCS”), the exclusive, national service provider to Camber for sales of our products at the 340B Ceiling Price. DCS will accept orders and provide logistics, invoicing, and customer support. Separately, DCS is also able to sell and distribute the referenced products to non-340B customers at commercial prices.

At this time, Clovis won’t be implementing its partnership with Kalderos to effectuate 340B drug discounted prices for 340B Contract Pharmacies. Clovis’ products remain available through all historically available channels.

Contact:
priceadmin@clovisoncology.com

Effective October 1, 2024, EMD Serono will eliminate the exception for wholly owned pharmacies; apply geographic mileage requirements (40 miles) to contract pharmacies under their policy; and apply their policy to all covered entity types other than Ryan White Clinics purchasing Serostim® (somatropin).

Contact: 
support@340BESP.com

Effective March 20th, 2024, EMD Serono will allow Arkansas-based covered entities to order 340B products and/or place “Bill to/Ship to” replenishment orders for Arkansas-based contract pharmacies.

Contact: 
support@340BESP.com

Received email confirmation that effective February 1, 2025, Kansas is no longer exempt from Lilly’s Contract Pharmacy Policy.  

Received email confirmation from Lilly that the following states are exempt from Lilly Contract Pharmacy Policy: Arkansas, Louisiana, Maryland, Minnesota, Mississippi, Missouri , and Kansas.

A notice was received from Eli Lilly that effective February 1, 2026, will require covered entities to submit CLD for all 340B dispenses, including in-house pharmacy dispensing. 

August 2024 Update: In August 2024, Lilly notified HRSA of Lilly’s intention to implement its obligation to offer the 340B ceiling price to covered entities through a rebate via a cash replenishment model, for an effective date of November 1, 2024. 

November 15, 2024 Update: Lilly sued HRSA over its purported rejection of Lilly’s plan to change the way it offers reduced prices on its medicines in the 340B program, through its technology partner Kalderos. 

Contact: 
340B@lilly.com

Effective July 1, 2024, Eli Lilly will only provide 340B priced products to a single contract pharmacy if the entity does not have an in-house pharmacy through the provision of claims data. Eli Lilly’s insulin policy remains the same.

Contact: 
340B@lilly.com

A notice was received from Exelixis, for an effective date of October 1, 2025, a change to their 340B contract pharmacy policy regarding wholly-owned (or affiliated contract pharmacies) and claims data submission requirements.

Effective July 1st, 2024, Exelixis will allow a hospital covered entity to designate a single contract pharmacy within their specialty pharmacy network if the entity does not have an in-house pharmacy or wholly-owned (or common ownership) contract pharmacy. Claims data must be provided for contract pharmacy 340B dispensations. Federal Grantees not subject to limitations

Contact: 
340B@exelixis.com

A notice was received from Genentech, with an effective date of May 31, 2025, changes to their Contract Pharmacy Policy including claims submission requirement for hospital covered entities and prohibition of redistribution of 340B drug. 

Effective May 1st, 2024, Genentech will only provide 340B pricing all Genentech products except Hemlibra and Evrysdi to a single Contract Pharmacy if the Covered Entity does not have an in-house pharmacy capable of dispensing 340B drugs. 
Federal Grantees are not subject to limitations.

Contact: 
support@340besp.com

Effective January 30th, 2024, Gilead will require covered entities to submit claims level data via 340BESP for their branded HCV products purchased at the 340B price for wholly-owned pharmacies.

Contact: 
support@340besp.com

A notice was received from GSK, with an effective date of January 2026, the launch of Exednsur (depemokimab-ulaa) that is part of a limited pharmacy network and will be incorporated into the GSK Contract Pharmacy Policy.

A notice was received from GSK, with an effective date of January 1, 2026, the exemption of specific covered entities within the state of New Mexico from their Contract Pharmacy Policy.

A notice was received from GSK, with an effective date of November 1, 2025, announcing the exemption of the state of Oklahoma from their Contract Pharmacy Policy.  

A second notice was received from GSK, with an effective date of 10/2/25, a change to their 340B contract pharmacy policy exempting Rhode Island. 

A notice was received from GSK, with varying effective dates, a change to their 340B contract pharmacy policy exempting Oregon (eff. 9/28/25).

A notice was received from GSK, with varying effective dates, a change to their 340B contract pharmacy policy exempting Maine (eff. 9/23/25). 

A notice was received from GSK, with varying effective dates, the exemption of the state of Colorado to their Contract Pharmacy Policy.

A notice was received from GSK, with varying effective dates, the exemption of the states of North Dakota to their Contract Pharmacy Policy.

A notice was received from GSK, with varying effective dates, the exemption of the states of Vermont to their Contract Pharmacy Policy.

A notice was received from GSK, with an effective date of April 9, 2025, the exemption of the state of Nebraska to their Contract Pharmacy Policy. 

A notice was received from GSK, with an effective date of May 7, 2025, the exemption of the state of Utah to their Contract Pharmacy Policy.

A notice was received from GSK, for an effective date of March 1, 2025, that the state of Kansas is no longer exempt from the Contract Pharmacy Policy. 

A notice was received from GSK, for an effective date of December 19, 2024 that GSK has voluntarily withdrawn the new drug application (NDA) for Jesduvroq (Daprodustat).  

Effective 08.28.24, GSK made a change to their 340B contract pharmacy policy regarding Missouri covered entities.

Effective August 28, 2024, GSK will exempt Missouri hospital covered entities from its 340B contract pharmacy policy 

Effective August 1, 2024, GSK will allow covered entities located in Minnesota to place “Bill to/Ship to” replenishment orders to their HRSA designated contract pharmacies located within the state. For specialty/oncology products part of the limited pharmacy network, the contract pharmacies must be a part of GSK’s limited pharmacy network. 

Contact: 
support@340besp.com

Effective August 1, 2024, GSK will allow covered entities located in Minnesota to place “Bill to/Ship to” replenishment orders to their HRSA designated contract pharmacies located within the state. For specialty/oncology products part of the limited pharmacy network, the contract pharmacies must be a part of GSK’s limited pharmacy network.

Contact: 
support@340besp.com

Effective July 1, 2024, GSK will allow covered entities located in Mississippi, Maryland, or Kansas to place “Bill to/Ship to” replenishment orders to their HRSA designated contract pharmacies located within the respective states. For specialty/oncology products part of the limited pharmacy network, the contract pharmacies must be a part of GSK’s limited pharmacy network.

Contact: 
support@340besp.com

Effective June 6th, 2024, GSK will allow West Virginia-based covered entities to place “Bill to/Ship to” replenishment orders to their HRSA designated contract pharmacies. For specialty/oncology products part of the limited pharmacy network, the contract pharmacies must be a part of GSK’s limited pharmacy network.

Contact: 
support@340besp.com

Effective 07.01.24, Jazz has updated their contract pharmacy policies for Arkansas, Louisiana, West Virigina, Maryland, Mississippi, Kansas, Minnesota, Missouri. 

Effective July 1, 2024, Johnson & Johnson will allow non-grantee entities located in Maryland and Mississippi to place “Bill to/Ship to” replenishment orders to their HRSA designated contract pharmacies located within the respective states through the provision of claims data.

Contact: 
340B_JJHCS@its.jnj.com

A notice was received from JnJ that effective April 7, 2025, Ustekinumab (unbranded Stelara) is now including in the Contract Pharmacy Policy.

November 12, 2024, Update:  JNJ filed a lawsuit against Health Resources and Services Administration (HRSA) due to their letter that was sent September 27, 2024, halting the rebate model.  

Effective 9/30/2024, Johnson and Johnson will postpone their 340B Rebate Program announced on 8/23/2024.  Additionally, effective 8/20/2024, their contract pharmacy policy will exempt Arkansas covered entities and include claims data submission.

Effective 9/30/2024, Johnson and Johnson will postpone their 340B Rebate Program announced on 8/23/2024.  Additionally, effective 8/20/2024, their contract pharmacy policy will exempt Arkansas covered entities and include claims data submission.

Contact: 
support@340besp.com

Effective July 1, 2024, Johnson & Johnson will allow non-grantee entities located in Maryland and Mississippi to place “Bill to/Ship to” replenishment orders to their HRSA designated contract pharmacies located within the respective states through the provision of claims data. 

Contact: 
support@340besp.com

A notice was received from Liquidia, with varying effective dates, the exemption of the states of Oklahoma and New Mexico from their Contract Pharmacy Policy. 

A notice was received from Liquidia, with varying effective dates, a change to their 340B contract pharmacy policy exempting Oregon (eff. Date 9/26/25), Maine (eff. Date 9/24/25), and Rhode Island (eff. Date 10/1/25)

A notice was received from Liquidia, with varying effective dates, a change to their 340B contract pharmacy policy exempting North Dakota and Colorado

A notice was received from Liquidia, effective July 1st, 2025, Liquidia will ship Yutrepia purchased at the 340B price exclusively to locations within Liquidia’s limited distribution network (Accredo or Caremark/CVS). Also, Hawaii, Tennessee, South Dakota, and Vermont will be exempt from their Contract Pharmacy Policy.

A notice was received from Liquidia, effective July 1st, 2025, Liquidia will ship Yutrepia purchased at the 340B price exclusively to locations within Liquidia’s limited distribution network (Accredo or Caremark/CVS). Also, Hawaii, Tennessee, South Dakota, and Vermont will be exempt from their Contract Pharmacy Policy.

A notice was received from Liquidia, effective June 1, 2025 a change to their 340B contract pharmacy policy. Liquidia will ship Yutrepia purchased at the 340B price exclusively to locations registered as a 340B covered entity or eligible child site location affiliated with that covered entity. Covered entity and Federal Grantee contract pharmacies will no longer be eligible recipients for Bill To / Ship To replenishment orders.

Effective 06.15.24, Liquidia will provide 340B pricing to an unlimited number of contract pharmacies for covered entities in the state of Arkansas, Kansas, Louisiana, Maryland, Minnesota, Mississippi, and West Virginia. 

Effective April 1st, 2024, Liquidia will only provide 340B priced Yutrepia to a single Accredo or Caremark/CVS Specialty Contract Pharmacy, if the covered entity doesn’t have an in-house pharmacy, with the provision of claims data.
*Effective date subject to FDA’s final approval for Yutrepia

Contact: 
support@340besp.com

A notice was received from Merck, a change to their 340B contract pharmacy policy for covered entities in New Mexico and also an update on the HRSA approved 340B Rebate Model Pilot.

An email notice was received from Merck, a change to their 340B contract pharmacy policy for covered entities in Maine, Oklahoma, Oregon, and Rhode Island.

An email notice was received from Merck, a change to their 340B contract pharmacy policy for covered entities in Vermont, Tennessee, Hawaii, and Colorado.

A notice was received from Merck, with varying effective dates, the exemption of the states of Utah, Nebraska, South Dakota, and North Dakota to their Contract Pharmacy Policy. 

An email notice was received from Merck, effective April 9, 2025, a change to their 340B contract pharmacy policy for covered entities in Nebraska.

A notice was received from Merck, effective July 1, 2025, a change to their 340B contract pharmacy policy for covered entities in South Dakota, as well as changes to the requirements for mandatory claim submissions. 

Effective 08.01.24, Merck made a change to their 340B contract pharmacy policy for covered entities in Minnesota. Effective August 28, 2024, a change to their 340B contract pharmacy policy for covered entities in Missouri. 

Merck will provide 340B priced products to an unlimited number of contract pharmacies for Minnesota covered entities effective August 1, 2024, and Missouri covered entities effective August 28, 2024, through the provision of claims data. For Winrevair, the specialty contract pharmac(ies) must be within Merck’s limited pharmacy network.

Federal Grantees (except CH grantee entities) are not subject to limitations.

Contact: 
340bdata@merck.com

Effective July 1, 2024, Merck will provide 340B priced products to an unlimited number of contract pharmacies for Maryland, Mississippi and Kansas covered entities through the provision of claims data. For Winrevair, the specialty contract pharmac(ies) must be within Merck’s limited pharmacy network.

Federal Grantees (except CH grantee entities) are not subject to limitations.

Contact: 
340bdata@merck.com

Effective June 6th, 2024, Merck will provide 340B pricing to an unlimited number of contract pharmacies for covered entities in the state of West Virginia. Winrevair will only be available through a limited specialty pharmacy network. 

Contact: 
340bdata@merck.com

Effective April 12th, 2024, Merck will include Winrevair in its 340B Contract Pharmacy Policy for hospitals or consolidated health center program covered entities and will be available through a limited specialty pharmacy network. The designated specialty pharmacy is in addition to the single contract pharmacy designation.

Federal Grantees (except CH grantee entities) are not subject to limitations.

Contact: 
340bdata@merck.com

On September 2, 2025, a notice was received from MTPA updating their 340B Contract Pharmacy Policy.

Effective July 17, 2024, Mallinckrodt will require a single contract pharmacy designation through FFF Enterprises, Inc. for Acthar ® claims for hospital covered entities using their limited distribution network.

Contact:

FFFCustomerCare@fffenterprises.com 

Effective July 1st, 2024, Novo Nordisk will allow a maximum of two (2) contract pharmacy designations for all covered entities (e.g. two retail CPs, two specialty CPs, one retail and one specialty CP) regardless of if the covered entity has an in-house pharmacy. Federal Grantees may utilize an unlimited number of contract pharmacies through the provision of claims data via 340B ESP. 
There are no changes to wholly-owned pharmacies.

Contact: 
support@340besp.com

Effective February 1st, 2024, Novo Nordisk updated its contract pharmacy policy for Arkansas hospital covered entities only. They will allow two contract pharmacy designations for all Arkansas hospital covered entities without the provision of claims data. With the provision of claims data, an unlimited number of contract pharmacies are allowed if they are located within the state of Arkansas.
Federal Grantees not subject to limitations

Contact: 
support@340Besp.com

340BInfo@novonordisk.com

Effective July 1st, 2023, Novo Nordisk will allow up to two contract pharmacy locations per 340B hospital (one retail, one specialty). Federal Grantees are not subject to limitations.

Contact: 
support@340BESP.com

Effective October 1, 2025 a change to their contract pharmacy policy for Rhode Island covered entities.

On October 14, a change to their contract pharmacy regarding products that are a part of a limited distribution network.

A notice was received from Novartis, effective September 24 a change to their contract pharmacy policy for Maine.

A notice was received from Novartis that effective August 1, 2025, North Dakota hospital covered entities will be able to order products and/or place “Bill to/Ship to” replenishment orders at the 340B price for products dispensed August 1, 2025, with respect to North Dakota based pharmacies with which they have contract pharmacy arrangements.

Effective August 6, 2025, a change was also made to their contract pharmacy policy for Colorado covered entities. 

On July 14, 2025, a notice was received from Novartis, effective immediately, clarifying their 340B Contract Pharmacy Policy (including Vermont, South Dakota, and Hawaii in the overall Contract Pharmacy Policy rather than individual state notification letters).

A notice was received from Novartis, clarifying their 340B Contract Pharmacy Policy for covered entities and their contract pharmacies in the State of Tennessee (please see attachment).

Effective June 11, 2025, Vermont hospital covered entities will be able to order products and/or place “Bill to/Ship to” replenishment orders at the 340B price for products dispensed June 11, 2025, with respect to Vermont based pharmacies with which they have contract pharmacy arrangements.

A notice was received from Novartis, effective June 1, a change to their 340B contract pharmacy policy for their definition of “in-house” pharmacy.

A notice was received from Novartis, for an effective date of 4/9/25, the exemption of Nebraska to their Contract Pharmacy Policy.

A notice was received from Novartis, effective immediately, a change to their 340B contract pharmacy policy for Missouri Covered Entities.

On January 14, 2025, HRSA notified Novartis that it rejected Novartis’s proposed rebate model. Novartis then entered litigation against HRSA over its purported rejection of Novartis’s plan to change the way it offers reduced prices on its medicines in the 340B program. 

Effective January 1, 2025, Novartis announced changes to its contract pharmacy policy to require data submission for Non-Grantee Covered Entities. Wholly Owned Contract Pharmacies are no longer exempt from Novartis policy, and covered entities located in Maryland are allowed to place “Bill to/Ship to” replenishment orders to their HRSA designated contract pharmacies.  

Effective 10.04.24, Novartis will allow hospital covered entities located in Louisiana to place “Bill to/Ship to” replenishment orders to their HRSA designated contract pharmacies.

Effective August 1, 2024, Novartis will allow hospital covered entities located in Minnesota to place “Bill to/Ship to” replenishment orders to their HRSA designated contract pharmacies.

Contact:

Novartis.340B@novartis.com

 

Effective July 8, 2024, Novartis will allow covered entities located in Mississippi to place “Bill to/Ship to” replenishment orders to their HRSA designated contract pharmacies located within Mississippi.

Contact: Novartis.340B@novartis.com

Effective March 20th, 2024, Novartis will allow Arkansas hospital covered entities to order 340B products and/or place “Bill to/Ship to” replenishment orders for Arkansas-based contract pharmacies.

Contact: Novartis.340B@novartis.com

A notice was received from Organon, with varying effective dates, the exemption of the States of Maine, Oregon, Rhode Island, and Oklahoma to their contract pharmacy policy.

A notice was received from Organon an update to their 340B Contract Pharmacy Policy with multiple state exemptions (Vermont, Hawaii, South Dakota, North Dakota, Colorado) with varying effective dates.

A notice was received from Organon, with varying effective dates, announcing the exemption of the states of Nebraska & Utah to their Contract Pharmacy Policy.

Effective December 1, 2024, Organon has made a change to their 340B contract pharmacy policy for HRSA-Funded Health Center (CH) grantees   support@340BESP.com

Effective 8.01.2024, Organon will exempt Minnesota covered entities from its 340B contract pharmacy policy, in addition to covered entities in Missouri as of 08.28.2024
support@340BESP.com

Effective June 6th, 2024, Organon will allow Kansas, Maryland and Mississippi-based covered entities to place “Bill to/Ship to” replenishment orders to unlimited contract pharmacies if claims level data is submitted via 340B ESP. Organon will allow West Virginia-based covered entities to place “Bill to/Ship to” replenishment orders to unlimited contract pharmacies without requiring claims submission.

Contact: 
support@340BESP.com

A notice was received from Pfizer, effective immediately, a clarification to their one contract pharmacy exemption, noting that wholesalers will continue to ship 340B priced products to your one registered contract pharmacy location, or as needed for injectable products, a ship to location listed on your OPAIS Covered Entity Parent or Child records as a “Street Address” or “Shipping Address” available at https://340bopais.hrsa.gov

A notice was received from Pfizer, with an effective date of November 1, 2025, a change to their 340B contract pharmacy with updates to their one contract pharmacy exemption.

A notice was received from Pfizer, with an effective date of July 1, 2025, the exemption of the state of South Dakota to their Contract Pharmacy Policy. 

A notice was received from Pfizer, with varying effective dates, a change to their 340B Contract Pharmacy Policy exempting Colorado. 

A notice was received from Pfizer, with varying effective dates, a change to their 340B Contract Pharmacy Policy exempting Hawaii.

A notice was received from Pfizer, with an effective date of August 1, 2025, the exemption of the state of North Dakota to their Contract Pharmacy Policy.

A notice was received from Pfizer, for an effective date of 4/9/25, the exemption of Nebraska to their Contract Pharmacy Policy.

 

A notice was received from Pfizer, for an effective date of May 7, 2025, a change to their 340B Contract Pharmacy Policy with updates for Utah 340B hospital covered entities.  

 

Two notices were received from Pfizer, for an effective date of April 1, 2025, a change to their 340B contract pharmacy policy reinstating Kansas and West Virginia to their Contract Pharmacy Policy Restrictions. 
 

A notice was received from Pfizer, for an effective date of April 1, 2025, a change to their 340B contract pharmacy policy for the addition of Paxlovid NDCS to the Contract Pharmacy Policy.

Effective August 28, 2024, Pfizer will exempt Missouri hospital covered entities from its 340B contract pharmacy policy 

Contact:
340BCP@pfizer.com

Effective July 1, 2024, Pfizer will allow Kansas 340B covered entities to access 340B ceiling price for Pfizer products affected by their contract pharmacy policy. For Vyndmax and Vyndaquel, the specialty contract pharmacies must be part of the VYNDA Network. For Pfizer’s oral oncology medications, the specialty contract pharmacy must be part of Pfizer’s DON.

Federal Grantees not subject to limitations.
 
Contact:
340BCP@pfizer.com

Effective July 1, 2024, Pfizer will allow Maryland 340B covered entities to access 340B ceiling price for Pfizer products affected by their contract pharmacy policy. For Vyndmax and Vyndaquel, the specialty contract pharmacies must be part of the VYNDA Network. For Pfizer’s oral oncology medications, the specialty contract pharmacy must be part of Pfizer’s DON.

Federal Grantees not subject to limitations.

Contact:
340BCP@pfizer.com

Effective July 1, 2024, Pfizer will allow Maryland 340B covered entities to access 340B ceiling price for Pfizer products affected by their contract pharmacy policy. For Vyndmax and Vyndaquel, the specialty contract pharmacies must be part of the VYNDA Network. For Pfizer’s oral oncology medications, the specialty contract pharmacy must be part of Pfizer’s DON.

Federal Grantees not subject to limitations.

Contact:
340BCP@pfizer.com

Effective July 1, 2024, Pfizer will allow Mississippi 340B covered entities to access 340B ceiling price for Pfizer products affected by their contract pharmacy policy. For Vyndmax and Vyndaquel, the specialty contract pharmacies must be part of the VYNDA Network. For Pfizer’s oral oncology medications, the specialty contract pharmacy must be part of Pfizer’s DON.
 
Federal Grantees not subject to limitations.

Contact:
340BCP@pfizer.com

Effective June 6th, 2024, Pfizer will allow West Virginia and Louisiana 340B covered entities to access 340B ceiling price for Pfizer products affected by their contract pharmacy policy.

Federal Grantees not subject to limitations.
 
Contact:
340BCP@pfizer.com

Effective May 6th, 2024, Pfizer will allow Arkansas hospital covered entities to order 340B products and place “Bill to/Ship to” replenishment orders at 340B ceiling prices for its registered contract pharmacies. For Vyndamax and Vyndaquel, they may engage in multiple VYNDA Network specialty contract pharmacy arrangements without providing limited claims data, and for oral oncology medicines (“DON”), they may engage in multiple DON Network specialty contract pharmacy arrangements without proving limited claims data.

Contact: 
support@340besp.com

A notice was received from Sandoz, for an effective date of February 1, 2026, regarding the addition of Ziextenzo and Cimerli to their Contract Pharmacy Policy.

An email communication was received from Sandoz, for an effective date of June 4, 2025, regarding the addition of Wyost and Jubbonti to their Contract Pharmacy Policy. 

An email communication was received from Sandoz, with varying effective dates, announcing the exemption of multiple states to their Contract Pharmacy Policy.

Effective July 1st, 2024, Sandoz will include Zarxio in its contract pharmacy policy.

Contact: 
support@340besp.com

A notice was received from Sanofi, effective November 24, 2025, the removal of the exemption of the state of Oklahoma to their Contract Pharmacy Policy.

A notice was received from Sanofi, effective November 1, 2025, the exemption of the state of Oklahoma from their Contract Pharmacy Policy. 

A notice was received from Sanofi, effective July 1, 2025, a change to their 340B Contract Pharmacy Policy exempting South Dakota and Vermont.

Effective February 1st, Sanofi announced that West Virigina and Kansas are subject to the contract pharmacy and claims data submission policy.  

November 22, 2024, Update: Sanofi announced it is transitioning to a 340B Credit Model for Hospital Covered Entities (CAH, DSH, RRC, SCH) as well as Consolidated Health Centers (CH). The Credit Model effective dates are below: 

January 6, 2025: CAH, DSH, RRC, SCH 

March 1, 2025: CH  

Beacon will be the platform to capture Claim Submission, Validation, and 340B Credit Payment Process.  

Sanofi also announced changes to their Contract Pharmacy Policy effective January 6, 2025, for Hospital Covered Entities and a March 1, 2025, effective date for Consolidated Health Centers.  

Contact: 
Sanofi340BOperations@Sanofi.com

Effective August 28, 2024, Missouri Covered Entities may access 340B pricing at an unlimited number of Missouri based contract pharmacies by submitting claims data through the 340B ESP™ platform for each of the Covered Entity’s contract pharmacy
arrangements in Missouri. Covered Entities that currently have a contract pharmacy designation in place through 340B ESP™ will have that designation canceled and must begin submitting claims data to have access to 340B pricing at their contract pharmacies. This policy is effective August 28, 2024. Contact: Sanofi340BOperations@Sanofi.com
 
Effective September 23, 2024,  Sanofi is requiring certain Arkansas-based 340B hospitals (CAH, DSH, RRC and SCH) to provide evidence or attestation that they “retain legal title to Sanofi 340B-priced drugs delivered to [their] contract pharmacies until the contract pharmacies dispense those drugs to 340B-eligible patients.” The 340B Integrity Initiative is for Arkansas based community pharmacies and certain Arkansas-based 340B hospitals only. Consolidated Health Center Program (CH) is exempt from the Arkansas-based policy. 
Contact: Sanofi340BOperations@Sanofi.com

Contact: 
Sanofi340BOperations@Sanofi.com

Effective September 23, 2024, Sanofi is requiring certain Arkansas-based 340B hospitals (CAH, DSH, RRC and SCH) to provide evidence or attestation that they “retain legal title to Sanofi 340B-priced drugs delivered to [their] contract pharmacies until the contract pharmacies dispense those drugs to 340B-eligible patients.” The 340B Integrity Initiative is for Arkansas based community pharmacies and certain Arkansas-based 340B hospitals only. Consolidated Health Center Program (CH) is exempt from the Arkansas-based policy.

Contact: 
Sanofi340BOperations@Sanofi.com

Effective August 28, 2024, Missouri Covered Entities may access 340B pricing at an unlimited number of Missouri
based contract pharmacies by submitting claims data through the 340B ESP™ platform for each of the Covered Entity’s contract pharmacy
arrangements in Missouri. Covered Entities that currently have a contract pharmacy designation in place through 340B ESP™ will have that designation canceled and must begin submitting claims data to have access to 340B pricing at their contract pharmacies. 

Sanofi340BOperations@Sanofi.com

Effective August 1, 2024, Sanofi will allow covered entities located in Maryland and Mississippi to place “Bill to/Ship to” replenishment orders to their HRSA designated contract pharmacies located within the respective states through the provision of claims data.

Contact: 
Sanofi340BOperations@Sanofi.com

Effective July 1st, 2024, Sanofi will only provide 340B priced product to a single contract pharmacy location if the hospital Covered Entity doesn’t have an in-house pharmacy via the provision of claims data. Wholly owned pharmacies may only access 340B pricing if the covered entity lacks an in-house pharmacy, the wholly owned pharmacy is designated as the single contract pharmacy, and claims data is submitted. Claims data is not required for Consolidated Health Center (CH) entities. All other Federal Grantees, Children’s Hospitals, and Free Standing Cancer Hospitals are not subject to limitations. 

Contact: 
Sanofi340BOperations@Sanofi.com

A notice was received from Sumitomo, effective immediately, a change to their 340B Contract Pharmacy Policy, removing Oklahoma from the list of excluded states.

A notice was received from Sumitomo with varying effective dates, a change to their Contract Pharmacy Policy.

Missouri exception to Sumitomo contract pharmacy policies with claims data from 45 days of dispense.
Contact: 
support@340besp.com

On July 3, 2024, Sumitomo announced it will allow covered entities in Kansas, Maryland, Minnesota, and Mississippi to please bill-to/ship-to replenishment orders at the 340B price to all contract pharmacies through the provision of claims data starting July 1, 2024. Sumitomo will also exempt covered entities in West Virginia starting June 6, 2024.

Contact: 
support@340besp.com

Kansas, Maryland, Minnesota, Mississippi exception to Sumitomo contract pharmacy policies with claims data from 45 days of dispense.

Contact: 
support@340besp.com

West Viriginia exception to Sumitomo contract pharmacy policies.

Contact: 
support@340besp.com

Effective May 1st, 2024, Sumitomo will only provide 340B pricing for Aptiom, Gemtesa, and Myfembree to a single specialty Contract Pharmacy located within 40 miles of the parent site if the Covered Entity does not have an in-house pharmacy location. Sumitomo will only provide 340B pricing for Orgovyx to a single specialty Contract Pharmacy within SMPA’s ORGOVYX limited distribution network if the Covered Entity does not have an in-house pharmacy location capable of dispensing specialty products.
Louisiana and Arkansas covered entities are not subject to limitations.

Contact: 
support@340besp.com

An email was received from Vertex, with varying effective dates, clarifying State exemptions to their contract pharmacy policy. Contact Vertex directly with questions. 

A notice was received from Vertex, with varying effect dates, provide an update to their Contract Pharmacy Policy. 

A notice was received from Vertex, effective immediately, a change to their 340B contract pharmacy policy to include its pain medicine, Journavx (suzetrigine).  

A notice was received from Vertex, effective immediately, a change to their 340B contract pharmacy policy to include its new CF medicine Alyftrek (vanzacaftor, tezacaftor, and deutivacaftor).

Effective 08.28.2024, Vertex has updated their contract pharmacy policies for Arkansas, Kansas, Louisiana, Maryland, Minnesota, Mississippi, West Virginia and Missouri.

Effective July 2nd, 2024, Vertex will only provide 340B pricing on its Cystic Fibrosis products to a single Contract Pharmacy of the Covered Entity does not have an in-house pharmacy. Covered Entities located in Arkansas, Kansas, Louisiana, Maryland, Mississippi, or West Virginia, as well as Federal Grantees, are not subject to limitations.

Contact: 
support@340besp.com

A notice was received from Viatris, with varying effective dates, a change to their Contract Pharmacy Policy surrounding state exemptions. 

Effective August 28, 2024, Viatris will exempt Missouri hospital covered entities from its 340B contract pharmacy policy

Contact: 
support@340besp.com

Effective August 1, 2024, Viatris will only provide 340B priced products to a single Contract Pharmacy if the Covered Entity does not have an in-house pharmacy location. Arkansas, Louisiana, West Virginia, Mississippi, Kansas, Maryland, and Minnesota covered entities are exempt from Viatris’ contract pharmacy policy. Federal Grantees, with the exception of Consolidated Health Centers (CH/CHC), not subject to limitations.

Contact: 
support@340besp.com

A notice was received from United Therapeutics, with an effective date of May 28, 2025, a change to their 340B Contract Pharmacy Policy, which has two components: a grandfathering requirement and a claims data requirement. In order to be permitted to submit contract pharmacy orders, a covered entity must comply with both requirements.

A notice was received from Sobi, effective November 1, 2025, the exemption of the state of Oklahoma from their Contract Pharmacy Policy. 

A notice was received from Sobi, effective August 6, 2025, a change to their contract pharmacy policy for Colorado & North Dakota covered entities.

A notice was received from Sobi, effective immediately, the exemption of the states of Maine, Oregon, and Rhode Island from their Contract Pharmacy Policy.

A notice was received from Sobi, with an effective date of May 6, 2025, announcing the exemption of multiple states to their Contract Pharmacy Policy.

Effective July 1st, 2024, Sobi will only provide 340B priced products to a single contract pharmacy located within 40 miles of the parent site if the covered entity doesn’t have an in-house pharmacy. Federal Grantees included in this policy.

Contact: 
support@340besp.com

Effective March 22nd, 2024, Takeda will include Ninlaro in its 340B Contract Pharmacy Policy. Only pharmacies in Takeda’s limited distribution network may be designated so the 40-mileage restriction does not apply.
Federal Grantees not subject to limitations

Contact:
support@340besp.com

A notice was received from Takeda, with an effective date of May 23, 2025, changes to their Contract Pharmacy Policy

Effective February 16th, 2024, Takeda will include Inclusig, Alunbrig and Fruzaqla in its 340B Contract Pharmacy Policy. Only pharmacies in Takeda’s limited distribution network may be designated so the 40-mileage restriction does not apply.
Federal Grantees not subject to limitations

Contact: 
support@340besp.com

A notice was received from Teva, with an effective date of April 21, 2025, the addition of Epysqli to their contract pharmacy policy.

A notice was received from Teva, for an immediate effective date, a change to their 340B contract pharmacy policy for Selarsdi. 

Effective May 20th, 2024, Teva will include Simlandi to its 340B Contract Pharmacy Policy.

Contact: 
support@340besp.com

Effective April 8th, 2024, Teva will include Alvaiz in its contract pharmacy policy.

Contact: 
support@340besp.com

Effective November 25, 2024, UCB has made a change to their 340B contract pharmacy policy for addition of claims data requirement for hospital covered entities and inclusion of federal grantees in the policy.

Contact: 
340B@ucb.com

Effective June 6th, 2024, UCB will provide 340B pricing for its products to an unlimited number of contract pharmacies located in West Virginia for covered entities in the state of West Virginia.

Contact: 
340B@ucb.com

Effective June 3rd, 2024, UCB will provide 340B pricing for its products to an unlimited number of contract pharmacies located in Arkansas for covered entities in the state of Arkansas.

Contact: 
340B@ucb.com